Considerations Following Locoregional Therapy in HCC
Considerations Following Locoregional Therapy in HCC
May 2015
- 64-year old obese female presented with fatigue and unexplained weight loss
- History of nonalcoholic fatty liver disease (NAFLD), then nonalcoholic steatohepatitis (NASH)
- Lab results: AFP= 1,500 IU/ml
- ECOG=1; Child-Pugh A
- CT revealed 1 large liver mass, right side of liver close to a major blood vessel
- No extrahepatic disease
- Liver-directed therapy with DEB-TACE was performed
- Patient reported abdominal pain following DEB-TACE and required analgesics; low-grade fever
- Patient had a complete response
- AFP= 200 IU/ml at follow up
February 2017
- Follow-up imaging showed progression and evidence of bone metastases
- Therapy was initiated with sorafenib at 400 mg BID
- Follow-up testing showed liver decompensation
Recent Videos
Related Content
FDA Receives Resubmitted NDA for Camrelizumab/Rivoceranib Combo in Unresectable HCC
September 24th 2024Article
A new drug application has been resubmitted to the FDA for the combination of camrelizumab and rivoceranib as a first-line treatment for unresectable hepatocellular carcinoma, following a complete response letter in May 2024.
Read More
